September 9, 2017 06:54 AM EDT
Bioregnum
Opinion

Al­ler­gan CEO gam­bles a multi­bil­lion-dol­lar fran­chise — and his com­pa­ny rep — on a high-stakes bet at an In­di­an casi­no op

Bioreg­num — The view from End­points News

Al­ler­gan CEO Brent Saun­ders scored some heavy­weight ku­dos last fall with a so­cial con­tract that con­demned …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

For­bion rais­es €2.1B for two new biotech funds af­ter se­ries of com­pa­ny ex­its

J&J trims pipeline, in­clud­ing two mid-stage neu­ro­science stud­ies

Mary­land biotech gets green light for stem cell-de­rived ther­a­py for di­a­betes, aim­ing to com­pete with Ver­tex

Ex­clu­sive: Biotech tools com­pa­ny rais­es $75M for pro­tein man­u­fac­tur­ing tech 

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times